Evaluating the Tumor Burden, Histological Changes, and Immune Landscape of Breast Cancer Post-neoadjuvant Chemotherapy: Insights From 50 Cases

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2025 Mar 10

PMID 40061852

Authors

Arasi Rajesh

Dharma Saranya Gurusamy

Rajalakshmi Manikkam

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a heterogeneous disease with variable responses to neoadjuvant chemotherapy (NACT). Evaluating the histopathological and immune changes in post-NACT breast cancer specimens is crucial for understanding treatment response and guiding further management. This study aims to assess tumor burden using the Residual Cancer Burden (RCB) index, examine histological alterations, evaluate immune activity through tumor-infiltrating lymphocytes (TILs), and analyze proliferative capacity via Ki-67 expression in post-NACT breast cancer specimens. A cross-sectional study of 50 modified radical mastectomy (MRM) specimens post-NACT was conducted. The histopathological analysis included tumor regression changes, stromal and cellular alterations, and nodal involvement. Immune response was assessed by quantifying TILs, and proliferation was measured using the Ki-67 index. Statistical correlations were made between clinicopathological parameters, TILs, and Ki-67 expression. Residual disease was detected in 39 cases (78%), and 11 cases (22%) had no residual disease. Among the 39 cases with residual disease, the majority were classified as RCB II (22 cases, 56%), 16 cases (41%) were classified as RCB III, and one case (3%) was classified as RCB I. Common histological changes post-NACT included fibrosis in 31 cases (62%), necrosis in 19 cases (38%), and infiltration by foamy histiocytes in 16 cases (32%). Malignant epithelial cells more frequently exhibited foamy cytoplasm (16 cases (41%) vs. two cases (5%); p=0.0003), hyperchromatic nucleus (26 cases (67%) vs. six cases (15%); p=0.0001), and prominent nucleoli (26 cases (67%) vs. four cases (10%); p=0.0001) compared to benign cells. Among the 39 cases with residual disease, low TIL and high Ki-67 expression were observed in 20 cases (51%), while 12 cases (32%) showed high TIL and low Ki-67. Residual tumors with high TIL and high Ki-67 (four cases, 10%) and low TIL and low Ki-67 (three cases, 8%) were less common. A significant inverse relationship was found between TIL levels and Ki-67 expression (p=0.0002), as tumors with low TIL were more likely to have high Ki-67 expression (20 cases, 51%), whereas those with high TIL more frequently exhibited low Ki-67 expression (12 cases, 32%). Post-NACT evaluation of tumor burden, immune landscape, and proliferation provides valuable prognostic insights. Integrating RCB, TILs, and Ki-67 into routine pathological assessment may aid patient stratification and guide personalized treatment strategies. Further large-scale studies are needed to validate these findings and improve therapeutic decision-making in breast cancer management.

References

Park C, Jung W, Koo J . Pathologic Evaluation of Breast Cancer after Neoadjuvant Therapy. J Pathol Transl Med. 2016; 50(3):173-80. PMC: 4876080. DOI: 10.4132/jptm.2016.02.02. View

Sethi D, Sen R, Parshad S, Khetarpal S, Garg M, Sen J . Histopathologic changes following neoadjuvant chemotherapy in various malignancies. Int J Appl Basic Med Res. 2013; 2(2):111-6. PMC: 3678690. DOI: 10.4103/2229-516X.106353. View

Dieci M, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V . Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014; 25(3):611-618. PMC: 3933248. DOI: 10.1093/annonc/mdt556. View

Dieci M, Radosevic-Robin N, Fineberg S, Van den Eynden G, Ternes N, Penault-Llorca F . Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group.... Semin Cancer Biol. 2017; 52(Pt 2):16-25. DOI: 10.1016/j.semcancer.2017.10.003. View

DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S . Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol. 2010; 22(3):582-587. DOI: 10.1093/annonc/mdq427. View

Chandler C, Liu T, Buckanovich R, Coffman L . The double edge sword of fibrosis in cancer. Transl Res. 2019; 209:55-67. PMC: 6545239. DOI: 10.1016/j.trsl.2019.02.006. View

Kaufmann M, von Minckwitz G, Mamounas E, Cameron D, Carey L, Cristofanilli M . Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2011; 19(5):1508-16. DOI: 10.1245/s10434-011-2108-2. View

Acs B, Zambo V, Vizkeleti L, Szasz A, Madaras L, Szentmartoni G . Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol. 2017; 12(1):20. PMC: 5320658. DOI: 10.1186/s13000-017-0608-5. View

Kim K, Lee K, Kim T, Chun Y, Lee T, Park H . Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014; 17(1):40-6. PMC: 3988341. DOI: 10.4048/jbc.2014.17.1.40. View

10.

Hamy A, Pierga J, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C . Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol. 2017; 28(9):2233-2240. DOI: 10.1093/annonc/mdx309. View

11.

Wang Y, Zong B, Yu Y, Wang Y, Tang Z, Chen R . Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy. Front Oncol. 2021; 11:668610. PMC: 8256666. DOI: 10.3389/fonc.2021.668610. View

12.

Masood S . Neoadjuvant chemotherapy in breast cancers. Womens Health (Lond). 2016; 12(5):480-491. PMC: 5373271. DOI: 10.1177/1745505716677139. View

13.

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

14.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

15.

Fraser Symmans W, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-22. DOI: 10.1200/JCO.2007.10.6823. View

16.

West N, Milne K, Truong P, Macpherson N, Nelson B, Watson P . Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011; 13(6):R126. PMC: 3326568. DOI: 10.1186/bcr3072. View

17.

von Minckwitz G, Schmitt W, Loibl S, Muller B, Blohmer J, Sinn B . Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res. 2013; 19(16):4521-31. DOI: 10.1158/1078-0432.CCR-12-3628. View

18.

Cui J, Li Y, Yang Y, Yang H, Dong J, Xiao Z . Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape. Biomed Pharmacother. 2024; 171:116203. DOI: 10.1016/j.biopha.2024.116203. View

19.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938):164-72. DOI: 10.1016/S0140-6736(13)62422-8. View